Loading
Acumen Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by RA CAPITAL MANAGEMENT, L.P., was filed 25 Jul 2023.
Acumen Pharmaceuticals, Inc.: what insiders have been doing
Acumen Pharmaceuticals, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Between 22 October 2025 and 22 October 2026, 17 insiders published 74 filings.
All open-market trades in the period are sales: 48 sales worth €535k, by 9 insiders, with no purchase on record. The largest single trade was a sale of €64k by OConnell Daniel Joseph, published on 7 January 2026.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
With 74 filings in twelve months, the company is more active than the median of 24 filings across the 3,171 companies we follow on the same exchange. Since 2021, the database holds 9 purchases and 66 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows -121.3 m USD of net income.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
146
Thresholds
n/a
Buy Volume
€86M
9 ops. · all time
Sell Volume
€1M
66 ops. · all time
Who traded when
BuySaleDerek M. Meisner18 sales
OConnell Daniel Joseph10 sales
Zuga Matt10 sales
Barton Russell8 sales
Siemers Eric6 sales
Derrell Porter3 sales
+3 other insiders
Since the insiders bought
- -52.0%Entry US$7.10 · Close at T+365 US$3.41
- -68.4%Entry US$18.90 · Close at T+365 US$5.98
- -68.4%Entry US$18.90 · Close at T+365 US$5.98
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Acumen Pharmaceuticals, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$7.60.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.75
Analyst consensus
5 analystsStrong buy
US$5.00Target US$7.60(+336%)US$10.00
Income statement
EBITDA-US$116.9M
Net income-US$121.3M0.0% margin
Valuation
PER (forward)-1.2x
P/Book2.2x
Beta0.33
Balance sheet & cash
Market capUS$126.2M
Total debtUS$31.3M
Free Cash Flow-US$115.6M
Debt / Equity55%
Profitability & ownership
ROE-120.5%
ROA-45.8%
% insiders6.8%
% institutions66.6%
Last declaration on 17 June 2026
Declarations146 total
13,040 shares@ US$2.32540.015% mcap40.5% of flowCommonSEC144:0001950047-26-006245
12,800 shares@ US$2.32639.4% of flowCommon StockSEC:0001628280-26-043987:2
6,460 sharesCommon StockSEC:0001628280-26-043987:0
6,460 shares@ US$2.34520.1% of flowCommon StockSEC:0001628280-26-043987:1
13,040 shares@ US$2.32540.5% of flowCommon StockSEC:0001628280-26-043987:4
13,040 sharesCommon StockSEC:0001628280-26-043987:3
12,800 shares@ US$2.32560.015% mcap39.4% of flowCommonSEC144:0001950047-26-006235
6,460 shares@ US$2.3450.0076% mcap20.1% of flowCommonSEC144:0001950047-26-006161
6,400 shares@ US$2.230112.8% of flowCommon StockSEC:0001628280-26-042280:0
6,400 shares@ US$2.23010.0074% mcap100.0% of flowCommonSEC144:0001950047-26-005810
35,500 shares0Common StockSEC:0001628280-26-041263:0
35,500 shares0Common StockSEC:0001628280-26-041273:0
35,500 shares0Common StockSEC:0001231919-26-000604:0
35,500 shares0Common StockSEC:0001628280-26-041268:0
35,500 shares0Common StockSEC:0001628280-26-041270:0
35,500 shares0Common StockSEC:0001628280-26-041272:0
35,500 shares0Common StockSEC:0001628280-26-041276:0
35,500 shares0Common StockSEC:0001628280-26-041281:0
6,060,606 shares@ US$3.3032.7% of flowCommon StockSEC:0001231919-26-000262:0
2,090 shares@ US$1.850.0020% mcap2.7% of flowCommon StockSEC:0001628280-26-016645:0
2,090 shares@ US$3.260.0035% mcap4.8% of flowCommon StockSEC:0001628280-26-016645:1
9,406 shares@ US$3.017.7% of flowCommon StockSEC:0001628280-26-014365:1
9,406 shares@ US$1.8512.1% of flowCommon StockSEC:0001628280-26-014365:0
15,085 shares@ US$3.0012.3% of flowCommon StockSEC:0001628280-26-003948:1
2,671 shares@ US$1.851.3% of flowCommon StockSEC:0001628280-26-003948:2
25 of 146 declarations
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc. is a United States-based biopharmaceutical company listed on the NASDAQ exchange in the United States. It is a clinical-stage company focused on developing novel therapies for Alzheimer’s disease, with a differentiated scientific thesis centered on toxic soluble amyloid-beta oligomers (AβOs). From an equity analysis perspective, Acumen is best viewed as an R&D-intensive, single-asset-led biotech with meaningful upside if its lead program continues to show clinical validation, but also elevated binary risk typical of small-cap neuroscience developers.
The company was founded in the United States and is headquartered in Newton, Massachusetts, placing it within the Boston-area biotech cluster. Its core business is the discovery and development of antibody-based therapeutics aimed at selectively binding AβOs, which the company believes are key drivers of Alzheimer’s pathology. Acumen’s lead candidate is sabirnetug (ACU193), a humanized monoclonal antibody designed to target these toxic oligomers. The company’s strategy is not only to advance sabirnetug through clinical development, but also to build a broader platform around enhanced delivery to the brain, including its Enhanced Brain Delivery (EBD™) approach intended to improve transport across the blood-brain barrier.
Read moreShow less
In competitive terms, Acumen operates in one of the most scrutinized and capital-intensive areas of biotechnology. The Alzheimer’s drug landscape is crowded with large pharmaceutical companies, emerging biotech peers, and alternative mechanisms of action. Acumen’s distinguishing factor is the specificity of its target biology: rather than broadly targeting amyloid plaque, it focuses on soluble oligomers believed to be more directly linked to neurotoxicity. That said, the company remains highly dependent on clinical readouts, safety and tolerability data, and its ability to secure sufficient funding to support long development timelines.
Recent business developments have been material. Acumen has continued to advance its Phase 2 ALTITUDE-AD trial for sabirnetug in early Alzheimer’s disease, with topline data expected in 2026. In 2025, the company announced a strategic collaboration with JCR Pharmaceuticals to develop an EBD-enabled Alzheimer’s therapy, expanding the platform beyond the lead asset. Acumen also published Phase 1 INTERCEPT-AD data indicating sabirnetug was generally well tolerated and showed target engagement. Most recently, in March 2026, the company announced approximately $35.75 million in private placement financing to support its pipeline and development activities. For investors, the key themes are platform optionality, clinical execution, and financing discipline in a high-risk, high-upside therapeutic area.
